Latest Information Update: 03 Jul 2001
At a glance
- Originator Genentech
- Class Antihaemorrhagics; Blood coagulation factors; Coagulants
- Mechanism of Action Blood coagulation factor stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Haemophilia
Most Recent Events
- 03 Jul 2001 Discontinued-Preclinical for Haemophilia in USA (Unknown route)
- 14 Dec 1994 Preclinical development for Haemophilia in USA (Unknown route)